Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus + diphtheria + pertussis + poliomyelitis + influenza + hepatitis A + hepatitis B + tick-borne encephalitis + meningococcal + pneumococcal-Dr. med. Micha Loebermann
- Development stage
- Preclinical
- Lead developer
- Dr. med. Micha Loebermann
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a specific vaccination protocol evaluated in a clinical trial (NCT03618641) led by Dr. med. Micha Loebermann at the University of Rostock. The study investigates the safety and immune response of a comprehensive set of prophylactic vaccines—targeting tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, and pneumococcal diseases—in patients with multiple sclerosis (MS). The primary objective is to determine if these standard, publicly recommended vaccines remain effective and safe when administered to MS patients undergoing various disease-modifying therapies. The vaccines used are commercially available products administered according to manufacturer instructions and public health guidelines.
- Other names
- prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)
02
Targets
HA (Hemagglutinin)HBsAg (Hepatitis B surface antigen)Diphtheria toxinPV3 (Sabin) (Poliovirus type 3 antigen)Hepatitis A virus capsid proteinTick-borne encephalitis virus antigensCPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on tetanus + diphtheria + pertussis + poliomyelitis + influenza + hepatitis A + hepatitis B + tick-borne encephalitis + meningococcal + pneumococcal-Dr. med. Micha Loebermann.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus + diphtheria + pertussis + poliomyelitis + influenza + hepatitis A + hepatitis B + tick-borne encephalitis + meningococcal + pneumococcal-Dr. med. Micha Loebermann.